[1]CurrentPatentAssignee:PFIZERINC-US2005/250761,2005,A1Locationinpatent:Page/Pagecolumn16-18
[1]CurrentPatentAssignee:PFIZERINC-US2005/250761,2005,A1Locationinpatent:Page/Pagecolumn18-20
[1]CurrentPatentAssignee:SOUTHEASTUNIVERSITY-CN110025789,2019,ALocationinpatent:Paragraph0120-0123
[1]CurrentPatentAssignee:LUOXINPHARMACEUTICALSGROUPSTOCKCOLTD-CN111978212,2020,A
Title: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology 20171101
Title: Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
Journal: Journal of medicinal chemistry 20160908
Title: Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era?
Journal: Drug design, development and therapy 20150101
Title: The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Journal: Investigational new drugs 20121201
Title: Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Journal: Molecular cancer therapeutics 20121001
Title: Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120920
Title: Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.
Journal: Critical reviews in oncology/hematology 20120901
Title: Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Journal: Molecular cancer therapeutics 20120901
Title: Irreversible protein kinase inhibitors: balancing the benefits and risks.
Journal: Journal of medicinal chemistry 20120726
Title: The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101001
Title: The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Journal: Cancer investigation 20100501
Title: Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Journal: Oncogene 20100422
Title: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Journal: Clinical lung cancer 20090701
Title: Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.
Journal: Molecular cancer therapeutics 20080701
Title: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Journal: Cancer research 20071215
Title: Engelman JA, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to ZD1839. Cancer Res. 2007 Dec 15;67(24):11924-32.
Title: Kalous O, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to Anti-Human HER2 and GW572016. Mol Cancer Ther. 2012 Sep;11(9):1978-87.
